Malaria
Conditions
Interventions
Dihydroartemisinin Piperaquine tablet
Artemether Lumefantrine
Negative control nil intervention
Sponsors
Amusan Abiodun
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (i) Age 1 to 15 years with symptoms compatible with acute uncomplicated Plasmodium falciparum infection (ii) P. falciparum parasitemia = 2,000 asexual forms of parasite per µL of blood, (iii) Body (axillary) temperature = 37.5°C, or history of fever within one to two days preceding presentation, (iv) Absence of other concomitant illnesses, (v) Absence of any history of antimalarial drug use within 2 weeks prior to presentation, (vi) Written informed consent from parents or guardians of participants.
Exclusion criteria
Exclusion criteria: (i) severe malaria, (ii) severe malnutrition, (iii) serious underlying diseases (renal, cardiac, or hepatic), (iv) known allergic reaction to study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment success or failure | — |
Secondary
| Measure | Time frame |
|---|---|
| Response of patient to treatment will be classified as follows: (i) adequate clinical and parasitological response (ACPR), (ii) late parasitological failure (LPF), (iii) late clinical failure (LCF) and (iv) early treatment failure (ETF), (v) Slow clearance will be defined as failure to clear parasitemia by day 3 (WHO, 2018). | — |
Countries
Nigeria
Contacts
Public ContactAbiodun Amusan
Lecturer
Outcome results
None listed